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Adherence Patterns to Extended Cervical Screening Intervals in Women
Undergoing HPV and Cytology Cotesting
Abstract
Although guidelines have recommended extended interval cervical screening using concurrent human
papillomavirus (HPV) and cytology (“cotesting”) for over a decade, little is known about its adoption into
routine care. Using longitudinal medical record data (2003-2015) from Kaiser Permanente Northern
California (KPNC), which adopted triennial cotesting in 2003, we examined adherence to extended interval
screening. We analyzed predictors of screening intervals among 504,202 women undergoing routine
screening, categorizing interval length into early (
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ABSTRACT  
Although guidelines have recommended extended interval cervical screening using concurrent 
human papillomavirus (HPV) and cytology (“cotesting”) for over a decade, little is known about 
its adoption into routine care. Using longitudinal medical record data (2003-2015) from Kaiser 
Permanente Northern California (KPNC), which adopted triennial cotesting in 2003, we 
examined adherence to extended interval screening. We analyzed predictors of screening 
intervals among 504,202 women undergoing routine screening, categorizing interval length into 
early (<2.5 years), adherent (2.5<3.5 years), or late (3.5<6.0 years). We also examined repeated 
early screening in a subgroup of 50,864 women. Predictors included: cohort year (defined by 
baseline cotest, 2003-2009), race/ethnicity, and baseline age. Compared to the 2003 cohort, 
women in the 2009 cohort were significantly less likely to screen early (aOR=0.22, 95% 
CI=0.21, 0.23) or late (aOR=0.46, 95% CI=0.45, 0.48). African American (AA) and Hispanic 
women were less adherent overall than Non-Hispanic White women, with increased early [(AA: 
aOR=1.21, 95%CI=1.17, 1.24) (Hispanic: aOR=1.08, 95%CI=1.06, 1.11)] and late screening 
[(AA: aOR=1.23, 95%CI=1.19, 1.27) (Hispanic: aOR=1.05, 95%CI=1.03, 1.08)]. Asian women 
were more likely to screen early (aOR=1.03, 95%CI=1.00, 1.05), and less likely to screen late 
(aOR=0.92, 95% CI=0.90, 0.94). Women aged 60-64 years were most likely to screen early for 
two consecutive intervals (aOR=2.06, 95%CI=1.88, 2.26). Our study found that widespread and 
rapid adoption of extended interval cervical cancer screening is possible, at least in managed 
care. Further research examining multilevel drivers promoting or restricting extended interval 
screening across diverse healthcare settings is needed. 
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INTRODUCTION 
Over the last two decades, cervical cancer screening guidelines have changed considerably from 
annual screening with cytology (“Pap” testing) to less frequent screening using concurrent 
testing with high-risk human papillomavirus (HPV) and Pap testing (“cotesting”), or Pap testing 
alone1-5. These shifts reflect a growing body of evidence documenting the limited benefit and 
increased potential harm conferred by more frequent screening2. The great majority of new 
infections with high-risk HPV types, the primary cause of cervical cancer6, will not result in 
cancer. Thus, reducing the frequency of screening helps to decrease potential harm by reducing 
unnecessary treatment of HPV infection-related cervical abnormalities that would likely resolve 
without medical intervention7,8. In addition to possible psychosocial harms, these treatments can 
result in adverse reproductive and pregnancy outcomes9,10. Furthermore, in comparison to 
cytology alone, HPV-based screening is substantially more sensitive and provides greater 
protection against invasive cervical cancer11,12, and thus provides additional benefit beyond 
reduced frequency of screening.  
 
Drawing from this evidence, the American Cancer Society (ACS)1 and the American College of 
Obstetricians and Gynecologists (ACOG)5 first included extended interval cotesting as an option 
for screening in 2002-2003, but did not exclude annual screening as an option. In contrast, more 
recent 2012 guidelines from the United States Preventive Services Task Force (USPSTF)2, 
ACS3, and ACOG4 all recommend against annual screening, and recommend that routine 
screening using cotesting or cytology alone not occur before three years. Two organizations, 
ACS and ACOG, go further to state that cotesting is the preferred screening strategy3,4.  
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Despite strong evidence and consensus guidelines, several studies have shown resistance to 
extended intervals. For women, higher levels of worry and perceived risk, limited knowledge, 
and history of abnormal Pap screening have been shown to be potential barriers to extended 
intervals13-16. A 2012 study reported that only 45% of physicians offer triennial cotesting to 
women aged 30 years and older, citing patient concerns as the primary factor hindering extended 
intervals17. A more recent 2014 study found that only 15.3% of providers recommended 
guideline-appropriate screening across all age groups18. Several provider-level barriers have also 
been identified including distrust of guidelines, longer years since medical school graduation, 
and concerns that extended intervals will negatively impact patient satisfaction and health, and 
reduce clinic volume18-21. While informative, most of these studies rely on self-report and do not 
directly measure screening using clinical records. Additionally, while there is some evidence that 
young women (18-29 years old) are screening less frequently22,23, little is known about screening 
intervals in the recommended cotesting age group (30-64 years old).   
 
In 2003, Kaiser Permanente Northern California (KPNC), a large integrated healthcare 
organization, shifted from annual Pap testing to 3-year interval cotesting as the preferred routine 
screening strategy for women aged 30-64 years old. Although 2012 guidelines recommend 
cotesting every five years, there is continued debate over this24, and to date, KPNC has continued 
to recommend triennial screening. The KPNC cervical screening program has been described in 
detail elsewhere25-27. These data have been pivotal in evaluating the effectiveness of cotesting as 
a screening strategy25,28 and in providing additional evidence for the revised 2012 guidelines2,3. 
In the present study, we use these data to examine adherence patterns to extended interval 
screening over time.  
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METHODS 
We used data from the KPNC cervical screening program, which includes all women, aged 30-
64 years, enrolled at KPNC who had at least one screening event in 2003-2015. As of the last 
update (December 31, 2015), the full dataset includes over 1 million women, over 2 million 
screening visits, and up to 13 years of follow-up per person. While the dataset is comprised of 
extracted medical record data from all KPNC women, only data regarding screening visits (visit 
dates, results of cytology and/or HPV test, and follow-up treatment to abnormal results), and 
baseline characteristics (patient age, race, and hysterectomy status) are available for analysis. 
 
To avoid biases due to differences in follow-up time, we only included women in the 2003-2009 
cohorts (N=805,668), with cohort enrollment defined by year of baseline screening event. In our 
primary analysis, we also excluded women who did not undergo cotesting at baseline (n=50,809) 
because annual screening was still recommended for women receiving cytology alone in 2003. 
We also excluded women without at least one additional screening event (within 6.0 years) after 
baseline (n=174,699) because we do not have KPNC enrollment data to distinguish non-
screeners from women who left KPNC. Lastly, we excluded women inappropriate for extended 
interval screening including women who at baseline a) reported a hysterectomy (n=17,588); b) 
had a previous history of CIN2 or worse (CIN2+) (n=952); or c) were HPV-positive (n=57,407) 
or CIN2+ (n=11). These exclusions resulted in a study population of 504,202 women eligible for 
extended interval screening. The KPNC institutional review board (IRB) approved use of these 
data, and the National Institutes of Health Office of Human Subjects Research and Albert 
Einstein College of Medicine deemed this study exempt from IRB review. 
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Measures  
The primary outcome was length of screening interval following baseline cotest. We determined 
length of screening interval by calculating the number of years between the baseline cotesting, 
T0, and sequential screening, T1. To examine screening in relation to KPNC guidelines, we 
collapsed screening intervals into three mutually exclusive groups: “early screeners” (interval 
length < 2.5 years), “adherent screeners” (interval length 2.5 years<3.5), and “late screeners” 
(interval length 3.5<6.0 years).  We also examined a second outcome, repeated early screening, 
among a subgroup of women who screened early in the first interval (T0-T1), had at least two 
screening events within 8.0 years after baseline cotest, and had their first baseline cotest in 2003-
2006 (n=50,864). Within this group, we classified women as repeated early screeners if they 
screened early in both the first interval (T0-T1) and second screening interval (T1-T2). For 
subgroup analysis, women who did not screen early in the first interval or who enrolled after 
2006 were excluded due to differences in follow-up time. Lastly, we calculated baseline 
screening modality (cotesting versus cytology only) in all women screened at KPNC 
(N=805,668) to provide an overview of cotesting uptake across 2003-2009 cohorts. 
 
In each analysis, we included three predictors: cohort (defined by the year of baseline cotest), 
patient baseline age (categorized into seven age groups ranging from 30-64 years of age), and 
patient race/ethnicity (categorized by census groups and as listed in the KPNC medical record). 
Due to the high proportion of missing data for race/ethnicity (20.1%), which is common in 
electronic medical records and likely not to meet the missing-at-random assumptions required for 
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imputing data29, we categorized these women as “unknown race/ethnicity” and retained them in 
all analyses. 
 
Statistical Analyses 
We conducted univariate analyses to calculate the distribution of screening behaviors across 
cohorts, and used bivariate analysis to compare cohorts at baseline using the Pearson X2 test of 
independence. We used similar analyses to describe and compare women identified as repeated 
early screeners to those women who screened early only in the first screening interval, and to 
calculate proportions of repeated early screening by predictors over time. 
 
We used bivariate and multivariate multinomial logistic regression analysis to examine the 
association between cotesting interval length and predictors.  Additionally, we used bivariate and 
multivariate logistic regression to examine associations between repeated early screening and 
predictors. For all models, we estimated odds ratios (ORs) and corresponding 95% confidence 
intervals (CIs), and tested for linear trends by cohort and by age (ptrend). To assess the potential 
impact of including women with missing race/ethnicity data, we conducted sensitivity analysis 
using only women with complete race data (n=402,716). We found no substantial differences in 
the point estimates or patterns for any model, and therefore report analyses using the full study 
population. We conducted all analyses in 2016 using StataSE 13.1 (College Station, TX). 
 
RESULTS 
Across all women screened from 2003-2009 at KPNC, 93.7% (754,859/805,668) underwent 
cotesting at baseline. In the 2003, the first year of triennial interval cotesting, 52.4% 
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(36,847/70,326) of screened women underwent cotesting at baseline. In 2004, the cotesting rate 
rapidly increased to 95.7% (157,890/165,017) and reached 99.0% (123,319/124,583) in the 2009.  
 
Among the 504,202 women eligible for extended interval screening, we identified the proportion 
of women in each cohort adhering to triennial interval screening (Figure 1; see Table S1, 
Supplemental Digital Content 1, for detailed characteristics of women). Adherent screening 
increased in each successive calendar year cohort, from 35.9% in the 2003 cohort to 63.7% in the 
2009 cohort (ptrend<0.001). This increase was primarily driven by a decrease in the proportion of 
early screeners, from 39.0% for the 2003 cohort to 15.9% for the 2009 cohort (ptrend<0.001). The 
decrease in the proportion of late screeners was more modest (ptrend=0.012), from 25.0% for the 
2003 cohort to 20.4% for the 2009 cohort, with the lowest proportion occurring in the 2007 
cohort (18.4%). 
 
Table 1 provides the results of the adjusted multinomial logistic regression model. We found a 
significant decreasing trend in early screeners across cohorts (ptrend<0.001), with women in the 
2009 cohort having the lowest likelihood of being an early screener (aOR=0.22, 95% CI=0.21, 
0.23) in contrast to women in the 2003 cohort, controlling for age and race/ethnicity. We 
observed a similar, but more modest, trend of late screeners across cohorts (ptrend=0.000), with 
women in the 2009 cohort being 54% less likely to screen late than women in the 2003 cohort 
(aOR=0.46, 95% CI=0.45, 0.48). 
 
We also found differences in screening patterns by age and by race/ethnicity. Although we did 
observe a moderate trend by age (ptrend<0.001), in comparison to women aged 30-34, the 
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likelihood of being an early screener was the least in women aged 55-59 years (aOR=0.55, 95% 
CI=0.53, 0.56), not the oldest age group (aOR=0.77, 95% CI=0.75, 0.80). Compared to women 
aged 30-34 years, women aged 55-59 years were 24% less likely to be a late screener 
(aOR=0.76, 95% CI=0.74, 0.78) and 60-64 years were 14% less likely to be a late screener 
(aOR=0.86, 95% CI=0.83, 0.89). In comparison to Non-Hispanic White (NHW) women, African 
American women were less adherent overall, being more likely to screen early (aOR=1.21, 95% 
CI=1.17, 1.24) and to screen late (aOR=1.23, 95% CI=1.19, 1.27). We observed similar patterns 
for Hispanic women, with an increased likelihood of screening early (aOR=1.08, 95% CI=1.06, 
1.11) and late (aOR=1.05, 95% CI=1.03, 1.08). Asian women were more likely to screen early 
(aOR=1.03, 95% CI=1.00, 1.06), and less likely to screen late (aOR=0.92, 95% CI=0.90, 0.94) 
than NHW women. 
 
Among women who screened early in the first screening interval (T0-T1) and enrolled in 2003-
2006, we observed moderate decreases in the proportion of women who screened early for two 
consecutive intervals (“repeated early screeners”) over time (see Table S2, Supplemental Digital 
Content 2, for detailed characteristics of early screeners). The percentage of repeated early 
screeners was the lowest in the 2006 cohort (25.5%), but only marginally lower than the 2003 
cohort (32.2%), and we observed a rise in repeated early screeners in the 2004 cohort (37.3%). In 
women aged 30-59 years, we observed marginal differences in the proportion of repeated early 
screeners across age groups over time (Figure 2). However, we observed a marked difference 
among women aged 60-64 years, who had the highest percentage of repeated early screeners 
across age groups in the 2003 (45.1%), 2004 (50.4%), 2005 (43.4%) and 2006 cohorts (40.0%).  
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Table 2 provides the results of the adjusted logistic regression model examining predictors of 
repeated early screening. In comparison to the youngest age group, women aged 60-64 had the 
greatest likelihood of being a repeated early screener (aOR=2.06, 95% CI=1.84, 2.23). By 
cohort, we observed an overall decreasing (but not consistent) trend (ptrend<0.001). In contrast to 
the 2003 cohort, we observed a significant increase in the odds of repeated early screening in the 
2004 cohort (aOR=1.24, 95% CI=1.17, 1.32), a slight, but insignificant, decrease in the 2005 
cohort (aOR=0.98, 95% CI=0.92, 1.04), and a significant decrease in the 2006 cohort 
(aOR=0.74, 95% CI=0.69, 0.80), after adjusting for age and race/ethnicity. In contrast to NHW 
women, Asian women were significantly more likely (aOR=1.14, 95% CI=1.08, 1.20), while 
Hispanic women were significantly less likely (aOR=0.91, 0.85, 0.97), to screen early for two 
consecutive intervals. 
 
DISCUSSION 
In this study, we provide novel empirical data documenting increased and relatively rapid 
clinical adoption of triennial interval cotesting for routine cervical screening over time. Given the 
number of studies documenting provider and patient resistance to extended intervals13-15, 17, our 
results are promising, at least for women in managed care. In contrast to other studies, which 
reported extended screening rates ranging from 6.3%15 to 24%13, our results show that most 
women at KPNC (over 63% in the 2009 cohort) were adherent to extended triennial interval 
screening. While our results are encouraging, the program at KPNC is particularly well poised to 
implement guideline changes in an efficient manner. Further research that captures specific 
system-level mechanisms (e.g. provider education, electronic health record reminders, 
incentives) by which KPNC achieved such rapid uptake is needed to understand how best to 
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compare and translate these findings to other healthcare systems. Additionally, KPNC triennial 
guidelines differ somewhat from national guidelines recommending even longer intervals23, and 
therefore our results might not reflect screening patterns in other settings. Furthermore, although 
most women in the 2009 cohort screened triennially, over 15 percent of women continued to 
cotest earlier than is recommended. While we cannot assess contributing factors in these 
analyses, given the documented roles of patient attitudes or provider recommendation in other 
studies, it is likely that a multitude of factors contributed to adherent and nonadherent patterns. 
Additional interventions that simultaneously aim to increase patient knowledge regarding the 
potential harms of overscreening30, and to address provider concerns regarding potential negative 
consequences (financial, health, or otherwise) of less frequent screening might further reduce 
early screening behaviors13,16.  
 
Our results regarding differences by age are somewhat divergent, but we hypothesize may reflect 
two competing forces. In line with health behavior theories that argue that past behavior is often 
the greatest predictor of future behavior31, it is reasonable that the oldest group of women, who 
have been screening annually for the greatest number of years, would be the hardest group in 
which to achieve behavior change. Our results analyzing repeated early screening support this 
theory. However, when examining just the first screening interval (T0-T1), we did not observe 
this pattern as clearly. Surprisingly, we observed a general decrease in the odds of early 
screening with increases in age, except for the oldest group, which had the second to highest 
odds of screening early. The increased frequency in the oldest group might be driven in part by 
guidelines, which recommend discontinuing screening at age 65 among women with adequate 
prior screening. It is possible that providers might be screening women aged 60-64 without 
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documented screening history more frequently before discontinuing screening. Beyond this 
oldest group, the general decrease in frequency by age might be linked in part to reproductive 
years. Younger women might have more frequent gynecologic needs related to family planning 
that could result in more frequent exams and testing. Providers might also be more strongly 
encouraging this age group to screen more frequently17. Across women, these factors in the 
younger groups might be countering the impact of habitual behavior, which would be stronger in 
the older groups. As such, multifocal interventions that address habitual behavior and provide 
comprehensive care without frequent screening might be needed to further increase adherent 
screening in all groups.  
 
In contrast to NHW women, Asian women were significantly more likely to be early screeners, 
and significantly less likely to be late screeners. Asian women were also significantly more 
likely to be repeated early screeners, highlighting an overall pattern of early screening in this 
population. African American and Hispanic women, however, were both more likely to screen 
early and to screen late in comparison to NHW women, indicating increased likelihood of non-
adherence overall.  There is little information on racial differences in screening interval length32-
34. However, based on extensive evidence documenting racial disparities in cervical screening 
rates34, 35, these results are somewhat difficult to interpret. While the overall pattern of greater 
non-adherence among African American and Hispanic women support evidence of disparities, 
the pattern of Asian women, who at the population level also have lower screening than 
NHWs36, is more difficult to interpret. There are known differences in cancer outcomes between 
Asian American subpopulations,37,38 and thus our broad categorization may be hiding any 
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intragroup disparities or differences due to income, acculturation and other factors39,40. Further 
research that examines interval patterns by race and by other socioeconomic factors is needed.  
 
For those women identified as late screeners, we observed less drastic changes over time. One 
factor that likely is shaping these patterns is that we only examined screening behaviors among 
women who had at least two screening events and thus are unable to fully examine 
underscreening. Additionally, although KPNC continued to recommend triennial cotesting after 
2012 guidelines, it is likely that these national shifts impacted interval patterns among women in 
the later cohorts. As such, the practice of screening later than is recommended by KPNC, but still 
screening within five years, does not raise substantial concern of underscreening in our view. 
Additional research is needed to fully examine any potential negative impact of extended interval 
screening on underscreening. 
 
Limitations 
In addition to strengths mentioned above, this study has limitations as well. We were unable to 
assess data from prior to 2003, and therefore cannot establish causality between KPNC guideline 
changes and adherence to cotesting guidelines. Additionally, due to study eligibility criteria, it is 
likely that women included in our analysis are different than those excluded in unmeasured 
ways. Although beyond the purpose of this study, we acknowledge that examining predictors of 
screening uptake across all women—rather than just behaviors of those who screened—would 
add insight and help identify any negative impact of guidelines shifts on screening uptake 
overall. Lastly, although we excluded all women who cotested positive (HPV+ or CIN2+) at any 
point in the study or had a history of CIN2+ at baseline, there is a possibility that some women 
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included in our analysis may have other clinical risk factors (e.g. HIV+) that support more 
frequent screening. However, given the size of the study population and the low prevalence of 
these risk factors, it is unlikely that our results would be meaningfully modified on this basis.  
 
Despite documented patient- and provider-level concerns, our study found that widespread and 
rapid adoption of extended interval cervical cancer screening is possible, at least in the context of 
managed care. Although our results are promising, further research examining the multilevel 
drivers that promote or restrict adoption of extended interval screening across diverse healthcare 
settings is needed to fully understand how to decrease overscreening and increase underscreening 
across populations.  
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Figure 1. Proportion of early, adherent, and late screening behaviors by cohort year, 2003-2009 
 
Note: Analysis in the figure limited to KPNC patients who had baseline cotest in 2003-2009, completed sequential 
screening within 6.0 years, cotested negative on all screenings since baseline, had no history of CIN2+ before or 
since baseline, and had not undergone a hysterectomy (N=504,202).  Screening behavior determined by length of 
interval between baseline cotest and subsequent screening (T0-T1). Interval length categorized into three screening 
behaviors based on KPNC guidelines: early (<2.5 years), adherent (2.5<3.5 years) and late (3.5<6.0 years). 
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Figure 2. Proportion of repeated early screeners by age group and cohort year, 2003-2006 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Percentage of repeated early screeners was calculated for each age group and for each cohort. The numerator 
included women categorized as repeated early screeners (defined as women who screened early (<2.5 years) in both 
the first (T0-T1) and second (T1-T2) intervals). The denominator included only a subgroup of women (n=50,864) 
from the larger analysis (patients who had baseline cotest in 2003-2006, screened early in the first interval (T0-T1), 
had two screening events within 8.0 years after baseline, cotested negative on all screenings since baseline, had no 
history of CIN2+ before or since baseline, and had not undergone a hysterectomy. 
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Table 1. Multinomial Logistic Regression Model for Screening Behaviors by Patient Characteristics (N=504,202) 
 
Early Screening (n=119,585) 
vs. Adherent Screening 
Late Screening (n=98,746) 
vs. Adherent Screening 
Characteristic    n aOR(95%CI)   n aOR(95%CI) 
Cohort (year of baseline cotest) 
2003 9,429 1.00 (ref) 6,048  1.00 (ref) 
2004 35,852 0.61 (0.59, 0.63) 20,453 0.54 (0.52, 0.56) 
2005 19,843 0.41 (0.40, 0.43) 14,551 0.48 (0.46, 0.49) 
2006 10,643 0.33 (0.31, 0.34) 10,393 0.51 (0.49, 0.53) 
2007 14,422 0.32 (0.31, 0.33) 12,258 0.44 (0.42, 0.46) 
2008 16,137 0.26 (0.25, 0.27) 17,963 0.46 (0.45, 0.48) 
2009 13,259 0.22 (0.21, 0.23) 17,080 0.46 (0.45, 0.48) 
Baseline Age (years) 
    
30-34 27,856 1.00 (ref) 18,715 1.00 (ref) 
35-40 19,140 0.76 (0.75, 0.78) 16,306 1.02 (0.99, 1.04) 
40-44 18,594 0.71 (0.69, 0.72) 16,825 1.01 (0.99, 1.04) 
45-49 18,482 0.69 (0.67, 0.70) 16,096 0.94 (0.92, 0.97) 
50-54 15,248 0.61 (0.60, 0.63) 14,290 0.90 (0.88, 0.93) 
55-59 12,229 0.55 (0.53, 0.56) 10,879 0.76 (0.74, 0.78) 
60-64 8,036 0.77 (0.75, 0.80) 5,635 0.86 (0.83, 0.89) 
Race/Ethnicity 
    
White 50,966 1.00 (ref) 42,327 1.00 (ref) 
African American 7,702 1.21 (1.17, 1.24) 7,028 1.23 (1.19, 1.27) 
American Indian 390 1.09 (0.97, 1.23) 429 1.39 (1.24, 1.56) 
Asian/Pacific Islander 18,466 1.03 (1.00, 1.05) 14,555 0.92 (0.90, 0.94) 
Hispanic 14,115 1.08 (1.06, 1.11) 11,785 1.05 (1.03, 1.08) 
Other 1,768 1.06 (1.00, 1.12) 1,592 1.10 (1.04, 1.17) 
Unknown 26,178 1.17 (1.15, 1.19) 21,030 1.14 (1.12, 1.16) 
Note: Analysis in the table used data from women eligible for extended screening intervals (N=504,202) which 
includes all KPNC women who had baseline cotest in 2003-2009, had a sequential screening within 6.0 years, 
cotested negative on all screenings since baseline, had no history of CIN2+ before or since baseline, and had not 
undergone a hysterectomy. Boldface indicate statistical significance (p<0.05). 
aMultinomial logistic regression model calculated the adjusted odds ratio (aOR) as a measure of association 
between screening behavior (early versus adherent and late versus adherent) and cohort, adjusting for age and 
race/ethnicity. The base group in multinomial regression model is adherent screening. 
bScreening behavior determined by length of interval between baseline cotest and subsequent screening (T0-T1). 
Interval length categorized into three screening behaviors based on guidelines: early (<2.5 years), adherent 
(2.5<3.5 years) and late (3.5<6.0 years). 
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Table 2. Logistic Regression Model for Repeated Early Screening by 
Patient Characteristics (n=50,864)a 
 
Repeated Early Screeningb 
(n=17,031) 
Characteristic n aOR(95% CI) 
Cohort (year of baseline cotest) 
2003 2,122 1.00 (ref) 
2004 8,928 1.24 (1.17, 1.32) 
2005 4,169 0.98 (0.92, 1.04) 
2006 1,812 0.74 (0.69, 0.80) 
Baseline Age (years) 
  
30-34 2,855 1.00 (ref) 
35-40 2,644 1.11 (1.04, 1.18) 
40-44 2,879 1.18 (1.11, 1.26) 
45-49 2,896 1.21 (1.14, 1.29) 
50-54 2,497 1.20 (1.12, 1.28) 
55-59 2,095 1.23 (1.14, 1.32) 
60-64 1,165 2.06 (1.88, 2.26) 
Race/Ethnicity 
  
White 7,914 1.00 (ref) 
African American 844 1.03 (0.94, 1.12) 
American Indian 48 0.92 (0.65, 1.29) 
Asian/Pacific Islander 2,753 1.14 (1.08, 1.20) 
Hispanic 1,714 0.91 (0.85, 0.97) 
Other 247 1.05 (0.90, 1.23) 
Unknown 3,511 1.21 (1.15, 1.27) 
Note: Analysis in the figure only included data on KPNC women who 
had baseline cotest in 2003-2006, screened early in the first interval 
(T0-T1), had two screening events within 8.0 years after baseline, 
cotested negative on all screenings since baseline, had no history of 
CIN+2 before or since baseline, and had not undergone a 
hysterectomy (n=50,864). Boldface indicates statistical significance 
(p<0.01).  
aLogistic regression model assessing association between repeated 
early screening and cohort year, adjusting for age and race/ethnicity. 
bRepeated early screening defined as women who screened early 
(<2.5 years) in both the first (T0-T1) and second (T1-T2) intervals). 
 
 
